Azalea Therapeutics
San Francisco, US · Founded 2023 · 36 employees on LinkedIn · 4 known investors
Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.
Founders & leadership
Azalea Therapeutics was founded in 2023 by Jennifer Doudna, Rodolphe Barrangou, Krishnendu Roy, and Connor Tsuchida.
JD
Jennifer DoudnaCo-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley
RB
Rodolphe BarrangouCo-founder, Associate Professor of Medicine, UCSF
KR
Krishnendu RoyCo-founder, Professor of Bioengineering, Stanford University
CT
Investors · 4
Competitors · 1
by search overlapCompanies competing with Azalea Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Biopharma Startup Funding (2026) – New Market Pitchnewmarketpitch.com · Jul 2026Frequently asked questions
- What does Azalea Therapeutics do?
- Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.
- Who founded Azalea Therapeutics?
- Azalea Therapeutics was founded by Jennifer Doudna, Rodolphe Barrangou, Krishnendu Roy, Connor Tsuchida in 2023.
- Who are Azalea Therapeutics's investors?
- Azalea Therapeutics's investors include Third Rock Ventures, RA Capital, Sozo Ventures, Yosemite.
- Where is Azalea Therapeutics headquartered?
- Azalea Therapeutics is headquartered in San Francisco, US.